AGEasy has made significant strides in addressing the pressing health concerns of seniors in India
The company recorded sales of Rs. 1,129 crore for the fiscal year ended June 30, 2024,
These digital initiatives are expected to enhance the accessibility and efficiency of drug safety monitoring and standards compliance
A committee to be formed to suggest measures for ensuring the safety of healthcare professionals
The emergence of new infections in India is a growing concern
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone
This two-day program was attended by 40 doctors & paramedical staff
Subscribe To Our Newsletter & Stay Updated